| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | nucleosome binding | 1.05e-03 | 98 | 10 | 2 | GO:0031491 | |
| GeneOntologyMolecularFunction | histone binding | 7.36e-03 | 265 | 10 | 2 | GO:0042393 | |
| MousePheno | scoliosis | 5.68e-04 | 64 | 8 | 2 | MP:0000161 | |
| MousePheno | abnormal vertebral body morphology | 6.04e-04 | 66 | 8 | 2 | MP:0000141 | |
| MousePheno | abnormal intervertebral disk morphology | 6.22e-04 | 67 | 8 | 2 | MP:0004173 | |
| MousePheno | abnormal symphysis morphology | 6.98e-04 | 71 | 8 | 2 | MP:0030877 | |
| MousePheno | abnormal exocrine gland morphology | 7.90e-04 | 853 | 8 | 4 | MP:0013558 | |
| MousePheno | abnormal cartilaginous joint morphology | 9.99e-04 | 85 | 8 | 2 | MP:0030875 | |
| MousePheno | abnormal response/metabolism to endogenous compounds | 1.49e-03 | 104 | 8 | 2 | MP:0003638 | |
| MousePheno | abnormal fibrous joint morphology | 2.50e-03 | 135 | 8 | 2 | MP:0030878 | |
| MousePheno | abnormal vertebrae morphology | 2.86e-03 | 546 | 8 | 3 | MP:0000137 | |
| MousePheno | abnormal spinal reflex | 2.99e-03 | 148 | 8 | 2 | MP:0012079 | |
| MousePheno | abnormal response to tactile stimuli | 2.99e-03 | 148 | 8 | 2 | MP:0005316 | |
| MousePheno | abnormal digestive system morphology | 3.16e-03 | 1233 | 8 | 4 | MP:0000462 | |
| MousePheno | abnormal reflex | 3.77e-03 | 1294 | 8 | 4 | MP:0001961 | |
| MousePheno | abnormal internal male genitalia morphology | 4.93e-03 | 1392 | 8 | 4 | MP:0009205 | |
| MousePheno | abnormal male reproductive system morphology | 5.24e-03 | 1415 | 8 | 4 | MP:0001145 | |
| MousePheno | abnormal male genitalia morphology | 5.24e-03 | 1415 | 8 | 4 | MP:0009198 | |
| MousePheno | abnormal sensory capabilities/reflexes/nociception | 6.26e-03 | 1486 | 8 | 4 | MP:0002067 | |
| MousePheno | digestive/alimentary phenotype | 6.48e-03 | 1500 | 8 | 4 | MP:0005381 | |
| MousePheno | abnormal total retina thickness | 6.66e-03 | 223 | 8 | 2 | MP:0011963 | |
| MousePheno | abnormal induced morbidity/mortality | 6.69e-03 | 737 | 8 | 3 | MP:0001657 | |
| Domain | KRAB | 1.49e-02 | 358 | 10 | 2 | PS50805 | |
| Domain | KRAB | 1.49e-02 | 358 | 10 | 2 | PF01352 | |
| Domain | KRAB | 1.58e-02 | 369 | 10 | 2 | SM00349 | |
| Domain | KRAB | 1.59e-02 | 370 | 10 | 2 | IPR001909 | |
| Pathway | WP_17Q12_COPY_NUMBER_VARIATION_SYNDROME | 7.19e-04 | 99 | 6 | 2 | M46448 | |
| Pathway | WP_FATTY_ACIDS_AND_LIPOPROTEINS_TRANSPORT_IN_HEPATOCYTES | 1.02e-02 | 381 | 6 | 2 | M48063 | |
| Pubmed | 6.76e-06 | 14 | 10 | 2 | 12438746 | ||
| Pubmed | Age-associated alteration of gene expression patterns in mouse oocytes. | 9.42e-05 | 51 | 10 | 2 | 15317747 | |
| Pubmed | 1.81e-04 | 1103 | 10 | 4 | 34189442 | ||
| Pubmed | The Deubiquitinase USP37 Regulates Chromosome Cohesion and Mitotic Progression. | 2.56e-04 | 84 | 10 | 2 | 26299517 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr17q12 | 4.63e-04 | 149 | 10 | 2 | chr17q12 | |
| Coexpression | MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_12 | 7.19e-06 | 11 | 10 | 2 | M16845 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.88e-04 | 150 | 10 | 2 | 7a9d6a7ff8000e9a061e1b586e4c258cc91a2a09 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.88e-04 | 150 | 10 | 2 | e5b843cb2bc847f6cab4cbec0a2a6a72fac50fee | |
| ToppCell | 368C-Myeloid-Macrophage-SPP1+_Macrophage|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 5.55e-04 | 160 | 10 | 2 | 6d941e584360975e1fdbb2fc67af8e31f18759d8 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Myeloid-Macrophage-macrophage,_alveolar-Macro_c6-VCAN|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.55e-04 | 160 | 10 | 2 | 8374ae912337947b2cc8d17d5840f306361fe1ff | |
| ToppCell | 368C-Myeloid-Macrophage-SPP1+_Macrophage|368C / Donor, Lineage, Cell class and subclass (all cells) | 6.48e-04 | 173 | 10 | 2 | bba8265a58f8f5659dc7b9da2fe27b15033fce34 | |
| ToppCell | droplet-Marrow-nan-18m-Hematologic-proerythroblast|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.48e-04 | 173 | 10 | 2 | 03cee3d24bc433e91a867ce951589de64a0538af | |
| ToppCell | droplet-Marrow-nan-18m-Hematologic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.78e-04 | 177 | 10 | 2 | 5d70fe2b0592362d664b3b4c84eb450ec2335957 | |
| ToppCell | droplet-Marrow-nan-18m-Hematologic-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.78e-04 | 177 | 10 | 2 | 48bcf603ec9593eedd81f3831cf9fde89fad368f | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_MHC|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.86e-04 | 178 | 10 | 2 | c90e9048fc786ba8559972ae25c25ecab4bc1b7c | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_MHC-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.86e-04 | 178 | 10 | 2 | 9e426ce23a4a33b91d139ad85685cf8483bcd01a | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Myeloid-Dendritic-conventional_dendritic_cell|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 7.41e-04 | 185 | 10 | 2 | 2aa5e9f6f167d27317a01d22392b59512333fa64 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Myeloid-Dendritic|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 7.41e-04 | 185 | 10 | 2 | 405bd4ba7ca7f7b625c49f1313ff946509e17c13 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_perichondrial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 8.05e-04 | 193 | 10 | 2 | e5016959f24370579a8770787e96869f264cf7b3 | |
| ToppCell | Control-Myeloid-MoAM4|Myeloid / Condition, Lineage and Cell class | 8.14e-04 | 194 | 10 | 2 | 7ab808dd1876b0eec2831caa16d04fd859b1dc50 | |
| ToppCell | Control-Myeloid-MoAM4|Control / Condition, Lineage and Cell class | 8.22e-04 | 195 | 10 | 2 | 211a736acbe875bd3c1942c62aaacc9b170ece6d | |
| ToppCell | Caecum-ILC|Caecum / Region, Cell class and subclass | 8.64e-04 | 200 | 10 | 2 | a9a1f03b4f415da860fb52eaedb07f0743692c98 | |
| ToppCell | Caecum-(3)_ILC-(30)_ILC|Caecum / shred on region, Cell_type, and subtype | 8.64e-04 | 200 | 10 | 2 | ccd323997613b65f0189c0c66d76fbf273e18c03 | |
| ToppCell | Caecum-ILC-ILC|Caecum / Region, Cell class and subclass | 8.64e-04 | 200 | 10 | 2 | 3ac18c3ef335cb83d6a826f6c7519a5e7804929d | |
| ToppCell | Caecum-(3)_ILC|Caecum / shred on region, Cell_type, and subtype | 8.64e-04 | 200 | 10 | 2 | 6857863b3200162c250123688af2cba681afcb35 | |
| Drug | Rodeo | 2.35e-05 | 17 | 10 | 2 | CID000038078 | |
| Drug | 20 alpha-hydroxycholesterol | 5.66e-04 | 82 | 10 | 2 | CID000121935 | |
| Drug | 4-nitro-phen-yl | 7.27e-04 | 93 | 10 | 2 | CID000119211 | |
| Drug | p-hydroxymandelonitrile | 1.15e-03 | 117 | 10 | 2 | CID000166768 | |
| Drug | benomyl | 1.37e-03 | 128 | 10 | 2 | CID000028780 | |
| Drug | Topo | 1.95e-03 | 153 | 10 | 2 | CID000065577 | |
| Drug | Pergolide mesylate [66104-23-2]; Up 200; 9.8uM; HL60; HT_HG-U133A | 2.29e-03 | 166 | 10 | 2 | 2403_UP | |
| Drug | Warfarin | 2.29e-03 | 166 | 10 | 2 | ctd:D014859 | |
| Drug | glycerol-3-phosphocholine | 2.45e-03 | 172 | 10 | 2 | CID000000823 | |
| Drug | Bromocryptine mesylate [22260-51-1]; Up 200; 5.4uM; HL60; HG-U133A | 2.48e-03 | 173 | 10 | 2 | 2007_UP | |
| Drug | molybdenum | 2.71e-03 | 181 | 10 | 2 | CID000023932 | |
| Drug | lipopolysaccharide, Escherichia coli O111 B4 | 2.92e-03 | 188 | 10 | 2 | ctd:C440499 | |
| Drug | Tolazamide [1156-19-0]; Up 200; 12.8uM; PC3; HT_HG-U133A | 3.14e-03 | 195 | 10 | 2 | 4003_UP | |
| Drug | Proadifen hydrochloride [62-68-0]; Up 200; 10.2uM; HL60; HT_HG-U133A | 3.17e-03 | 196 | 10 | 2 | 2707_UP | |
| Drug | Bromopride [4093-35-0]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 3.20e-03 | 197 | 10 | 2 | 3617_UP | |
| Drug | Methacycline hydrochloride [3963-95-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A | 3.20e-03 | 197 | 10 | 2 | 4143_UP | |
| Drug | Letrozole [112809-51-5]; Up 200; 14uM; PC3; HT_HG-U133A | 3.20e-03 | 197 | 10 | 2 | 4240_UP | |
| Drug | Nilutamide [63612-50-0]; Up 200; 12.6uM; PC3; HT_HG-U133A | 3.23e-03 | 198 | 10 | 2 | 6763_UP | |
| Drug | 0317956-0000 [391210-11-0]; Up 200; 10uM; MCF7; HT_HG-U133A | 3.27e-03 | 199 | 10 | 2 | 3966_UP | |
| Drug | Bendroflumethiazide [73-48-3]; Up 200; 9.4uM; MCF7; HT_HG-U133A | 3.27e-03 | 199 | 10 | 2 | 3934_UP | |
| Drug | Furazolidone [67-45-8]; Up 200; 17.8uM; HL60; HT_HG-U133A | 3.30e-03 | 200 | 10 | 2 | 3019_UP | |
| Drug | methenamine silver | 3.33e-03 | 201 | 10 | 2 | CID000004101 | |
| Drug | phosphorylcholine | 3.33e-03 | 201 | 10 | 2 | CID000001014 | |
| Disease | Endometrioma | 1.29e-03 | 161 | 10 | 2 | C0269102 | |
| Disease | Endometriosis | 1.29e-03 | 161 | 10 | 2 | C0014175 | |
| Disease | type 2 diabetes mellitus (is_implicated_in) | 1.46e-03 | 171 | 10 | 2 | DOID:9352 (is_implicated_in) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| VKYCGYCKYHFSKMK | 171 | P55198 | |
| CYKMNTKGNKFGYCK | 526 | Q9H2U9 | |
| MKNYKGYEKKPYCNA | 41 | Q14847 | |
| MEQGSCKKYIYLNKY | 426 | P22413 | |
| YFQYPANIIKMKKCY | 321 | Q13093 | |
| MAYSQGGGKKKVCYY | 1 | Q92769 | |
| GCTYSKAQNQKKMYY | 531 | Q86UG4 | |
| YCKGEKCYKYIKYSK | 141 | Q13360 | |
| QKMYPGEKAYECAKF | 121 | Q6P3V2 | |
| MKDLGYGKGYKYNPM | 626 | Q96S55 |